Chart of the Week: Rare Disease Activity Sample (LSDs)

We have recently noticed a trend among our customers. We have been successfully addressing some key use cases of our customers focused on rare and orphan diseases. This is an interesting coincidence since rare diseases played such a key role in our recently published...

FDA Regulation to Support the Next Wave in Diagnostics

In February of last year the FDA hosted a two-day workshop focused on technical and regulatory considerations related to the use of next generation sequencing (NGS) diagnostics in clinical practice.  This was a very forward-thinking move on the part of FDA, as...

Chart of the Week: Can Liquid Biopsy Screen for Disease?

We believe that the holy grail of liquid biopsy is screening capability in urine samples. In preparation for our liquid biopsy webinar at the end of this month we’ve been analyzing information on the state of liquid biopsy. For some of the up-and-comer liquid...